Dictogloss를 이용한 표현 연습이 중학교 영어 학습자의 관사 습득에 미치는 영향

강현아 이화여자대학교 교육대학원 2004 이화교육논총 Vol.14 No.-

'Focus on form' instruction, which draws learners' attention to a specific language form in a communicative context, is an effcet way to teach foreign language in classroom. It corresponds with the goals of the Korean National 7th Curriculum that aims at both fluency and accuracy. In language learning processing, output as well as input shjould be considered, because the lack of opportunities to produce the learned prammatical items blocks acquisition. Among 'focus on form' task and techniques, dictogloss, is an output-focused task requiring collaborative tasks and encouragnin students to reflect on their own output. English article that it is difficult to acqurire is related with communicative competence rather than linguistic competence. In addition, accurate article use does not really become important English articles effectively. This study aims at investigating the effects of dictogloss on the Korean middle school students' comprehension of English article and ability to use article in writing. A experimental group and a control group participated in this experiment for ten weeks. These groups were divided into upper and lower levels respectively. The control group was given only consciousness-raising activities with input enhancement materials whereas the experimental proup also took part in dictogloss task and produced their own output. The results of the experimen6al conducted in this study are as follows: First, the result showed that both groups showed meaningful increase, but output proup didn't achieve significantly better improvement in their grammatical judgement test, that is, comprehension posttest than the control group. Therefore, it can be conbducted that the balance between input and output in teaching and learning of English article is needed. Second, the output group using dictogloss showed the better improvement than the control group. Especially, the upper level students in out group outperformed the ones in the control group. It can be seen that output focused practice is important on the use of English article. We can conclude that it is necessary to give students a lot of opportunities to use English. Third, the qualitative analysis of the reconstruction stage of dictogloss showed that students in output group noticed the target form, English article and formulated thier own hypothesis and tried hypothesis testing through dictogloss. This means that the learning of English article using dictogloss had posistive effect as a output focused task. Thus, some implications can be drawn for English article teaching and learning. We can find that for the positive effect of dictogloss on students' acqusition of English article. the students' level and features of the target form should be considered. Teachers should make students understand the task itself and give them adequate feedback after the activity. And with the balance between input and output, various activities are needed according to learners' variables. Additional research should include deeper interview with each student. The research on the effective use of dictogloss on other grammatical items is aoso left for the further investigation.

프로스카 정(피나스테리드 5mg)에 대한 푸로케어 정의 생물학적 동등성

강현아,조혜영,이용복 한국약제학회 2006 Journal of Pharmaceutical Investigation Vol.36 No.2

암치료에 있어서 체질과 항암효과에 관한 한의학적 연구

성현제,신현규,박갑주,강봉주,은영아,김은해,정세영 한국한의학연구원 1997 한국한의학연구원논문집 Vol.3 No.1

As one of the chemical and experimental study on cancer treatment in Korea oriental medical hospital. Furthermore, we carried out the cytotoxicity test of extracts of herbal medicine. The results are as follows : About Clinical Aspects of the Oriental Medical Cancer Treatment - (1) Clinical experience is that 420 Oriental medical hospital were surveyed. Number of cancer patient treated by one oriental medical doctor was under 10(about 60%) or from 10 to 20(about 30%). (2) Diagnostic Procedure is that more than 80% of cancer patients were diagnosed by medical doctor of western hospital. (3) Therapeutic Method is that combination of oriental and western medical treatment was used in oriental medical hospital. (4) Relationship between cancer and constitutions is that to the relationship between cancer and constitutions, about 75% responded and most were considered to be Um. About Experimental Study - to evaluate the direct cytotoxicity of hot water and methanol extracts of 34 oriental medical presciptions on stomach cancer cell, SRB assay was carried out. (1) The IC50 value of water extract of Samsoum was 19㎍/㎖ and that of methanol extract was 15㎍/㎖, so that we confirmed Samsoum has a strong direct cytotoxicity. (2) The IC50 values of water extract of Coptidis Rhizoma, methanol extract of Caesalpiniae Lignum and Draba Semen were 10㎍/㎖, 19㎍/㎖ and 12.5㎍/㎖ respectively, so that we confirmed Coptidis Rhizoma, Caesalpiniae Lignum and Draba Semen have a strong direct cytototoxicity. (3) The IC50 value of combinatory prescription of Rhei Rhizoma, Forsythie Fructus and Caesalpiniae Lignum was about 40㎍/㎖.

체내동태 연구를 위한 혈청 중 펜톡시필린의 HPLC 정량법 개발 및 검증

조혜영,강현아,류희두,이화정,문재동,이용복 한국약제학회 2006 Journal of Pharmaceutical Investigation Vol.36 No.2

레보프라이드 정(레보설피리드 25㎎)에 대한 레보피드 정의 생물학적 동등성

조혜영,강현아,문재동,이용복 한국약제학회 2002 Journal of Pharmaceutical Investigation Vol.32 No.2

Levosulpiride is the levo-enantiomer form of racemic sulpiride, a benzamide derivative selectively inhibiting dopaminergic D_2 receptors at the trigger zone both in the central nervous system and in the gastrointestinal tract. The purpose of the present study was to evaluate the bioequivalence of two levosulpiride tablets, Levopride (SK Pharmaceutical Co., Ltd.) and Levopid (Dae Won Pharmaceutical Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). The levosulpiride release from the two levosulpiride tablets in vitro was tested using KP VII Apparatus Ⅱ method with various different kinds of dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty eight normal male volunteers, 23.82±3.26 years in age and 69.13±8.58 kg in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After one tablet containing 25 mg of levosulpiride was orally administered, blood was taken at predetermined time intervals and the concentrations of levosulpiride in serum were determined using HPLC method with fluorescence detector. The dissolution profiles of two levosulpiride tablets were very similar at all dissolution media. Besides, the pharmacokinetic parameters such as AUC_t, C_max and T_max were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed AUC_t and C_max and untransformed T_max. The results showed that the differences in AUC_t, C_max and T_max between two tablets based on the Levopride were -1.17%, 1.20% and -1.09%, respectively. There were no sequence effects between two tablets in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g., log(0.93)∼log(1.07) and log(0.90)∼log(1.14) for AUC_t and C_max, respectively). The 90% confidence interval using untransformed data was within ±20% (e.g., -19.47∼16.20 for T_max). All parameters met the criteria of KFDA guideline for bioequivalence, indicating that Levopid tablet is bioequivalent to Levopride tablet.

디푸루칸 캅셀(플루코나졸 50 mg)에 대한 플루코나 캅셀의 생물학적 동등성

조혜영,강현아,이석,오인준,임동구,문재동,이용복 한국약제학회 2003 Journal of Pharmaceutical Investigation Vol.33 No.2

Fluconazole is an orally active bis-triazole antifungal agent, which is used in the treatment of superficial and systemic candidiasis and in the treatment of cryptococcal infections in patients with the acquired immuno deficiency syndrome (AIDS). The purpose of the present study was to evaluate the bioequivalence of two fluconazole capsules, Diflucan(Pfizer Pharmaceuticals Korea Inc.) and Flucona (Korean Drug Pharmaceuticals Co., Ltd.), according to the guidelines of Korea Food and Drug Administration(KFDA). The fluconazole release from the two fluconazole capsules in vitro was tested using KP Ⅶ Apparatus Ⅱ method at 0.1M hydrochloride dissolution media. Twenty normal male volunteers, 23.60±1.88 years in age and 63.57±6.17㎏ in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After three capsules containing 50㎎ as fluconazole was orally administered, blood was taken at predetermined time intervals and the concentrations of fluconazole in serum were determined using HPLC method with UV detector. The dissolution profiles of two fluconazole capsules were very similar at 0.1M hydrochloride dissolution media. Besides, the pharmacokinetic parameters such as AUC_t, C_max and T_max were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed AUC_t and C_max and untransformed T_max. The results showed that the differences in AUC_t, C_max and T_max between two capsules based on the Diflucan were 4.96%, 5.65% and -13.76%, respectively. There were no sequence effects between two capsules in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g., log(1.01)∼log(1.08) and log(1.00)∼log(1.12) for AUC_t and C_max respectively), indicating that Flucona capsule is bioequivalent to Diflucan capsule.

스프렌딜 지속정(펠로디핀 5㎎)에 대한 스타핀 지속정의 생물학적동등성

조혜영,강현아,이석,백승희,박은자,최후균,문재동,이용복 한국약제학회 2003 Journal of Pharmaceutical Investigation Vol.33 No.4

Felodipine is a calcium antagonist that lowers blood pressure by reducing peripheral resistance by means of a direct, selective action on smooth muscle in arterial resistance vessels. Furthermore, it have been approved for the effective in angina pectoris and cardiac failure. The purpose of the present study was to evaluate the bioequivalence of two felodipine extended release (ER) tablets, Splendil (YuHan Corporation) and Stapin (Hana Pharmaceutical Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). THe felodipine release from the two felodipine formulations in vitro was tested using KP Ⅷ Apparatus Ⅱ method at pH 6.5 buffer solution. Twenty six healthy male subjects, 22.73±1.78 years in age and 66.66±7.28 ㎏ in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After two tablets containing 5 ㎎ as felodipine were orally administered, blood sample was taken at predetermined time intervals and the concentrations of felodipine in serum were determined using column-switching HPLC method with UV detector. The dissolution profiles of two formulations were similar at pH 6.5 buffer solution. Besides, the pharmacokinetic parameters such as AUG_(t), C_(max) and T_(max) were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed AUC_(t) and C_(max) and untransformed T_(max). The results showed that the differences between two formulations based on the Splendil were 2.53%, 1.32% and 18.32% for AUC_(t), C_(max) and T_(mzx), respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g., log(0.86)∼log(1.20) and long(0.89)∼long(1.23) for AUC_(t) and C_(max), respectively). Thus, the criteria of the KFDA guidelines for the bioequivalence was satisfied, indicating Stapin ER tablet and Splendil ER tablet are bioequivalent.

시클러 캡슐(세파클러 250㎎)에 대한 경보세파클러 캡슐의 생물학적동등성

조혜영,강현아,김세미,박찬호,오인준,임동구,문재동,이용복 한국약제학회 2005 Journal of Pharmaceutical Investigation Vol.35 No.1

The purpose of the present study was to evaluate the bioequivalence of two cefaclor capsules, Ceclor (Lilly Korea Co., Ltd.) and Kyongbocefaclor (Kyongbo Pharm. Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The release of cefaclor from the two cefaclor formulations in vitro was tested using KP VIII Apparatus II method with various dissolution media (pH 1.2. 4.0. 6.8 buffer solution and water). Twenty four healthy male subjects. 22.96±1.52 years in age and 67.03±7.90 kg in body weight, were divided into two groups and a randomized 2x2 cross-over study was employed. After one capsule containing 250 mg of cefaclor was orally administered, blood was taken at pre-determined time intervals and the concentrations of cefaclor in serum were determined using HPLC method with UV detector. The dissolution profiles of two formulations were similar at all dissolution media. In addition. the pharmacokinetic parameters such as AUC_(t), C_(max) and T _(max) were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed AUC_(t). C_(max) and untransformed Tmaa. The results showed that the differences between two formulations based on the reference drug, Ceclor. were -1.90%, 2.68% and -7.60% for AUCt, C_(max) and T_(max), respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log 0.8 to log 1.25 (e.g., log 0.91-log 1.06 and log 0.92-log 1.18 for AU', and C_(max), respectively). Thus. the criteria of the KFDA bioequivalence guideline were satisfied, indicating Kyongbocefaclor capsule was bioequivalent to Ceclor capsule.

유한세프라딘 캅셀(세프라딘 500mg)에 대한 브로드세프 캅셀의 생물학적 동등성

조혜영,이석,강현아,오인준,임동구,문재동,이용복 한국약제학회 2002 Journal of Pharmaceutical Investigation Vol.32 No.3

Cephradine is a first generation cephalosporin and has broad spectrum antibacterial activity against gram-positive and gram-negative microorganisms, through inhibition of bacterial cell wall synthesis. Cephradine is useful for treatment of infections of the urinary and respiratory tract, skin and soft tissues. The purpose of the present study was to evaluate the bioequivalence of two cephradine capsules, Cefradine Yuhan(YuHan Corporation) and Broadcef (Ilsung Pharmaceuticals Co. Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). The cephradine release from the two cephradine capsules in vitro was tested using KP Ⅶ Apparatus Ⅱ method with various different kinds of dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty normal male volunteers, 23.10±2.90 years in age and 67.69±8.04 ㎏ in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After one capsule containing 500㎎ as cephradine was orally administered, blood was taken at predetermined time intervals and the concentrations of cephradine in serum were determined using HPLC method with UV detector. The dissolution profiles of two cephradine capsules were very similar at all dissolution media. Besides, the pharmacokinetic parameters such as AUC_t, C_max and T_max were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed AUC_t and C_max and untransformed T_max. The results showed that the differences in AUC_t C_max and T_max between two capsules based on the Cefradine Yuhan were -2.87%, -0.96% and -4.85%, respectively. There were no sequence effects between two capsules in these parameter. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g.,log(0.93)∼log(1.02) and log(0.88)∼log(1.13) for AUC_t and C)max, respectively). The 90% confidence interval using untransformed data was within ±20% (e.g., -17.54∼7.78 for T_max). All parameters met the criteria of KFDA guideline for bioequivalence, indicating that Broadcef capsule is bioequivalent to Cefradine Yuhan capsule.

엘도스 캡슐(에르도스테인 300mg)에 대한 엘브론 캡슐의 생물학적 동등성

조혜영,이석,강현아,문재동,이용복 한국약제학회 2003 Journal of Pharmaceutical Investigation Vol.33 No.3

Erdosteine, the thiol derivatives chemically related to cysteine, is a mucolytic and mucoregulator agent which modulated mucus production and viscosity and increases mucoiliary transport. The purpose of the present study was to evaluate the bioequivalence of two erdosteine capsules, Erdos (Dae Woong Pharmaceutical Co., Korea) and Erblon (Kuhn Ⅱ Pharmaceutical Co., Korea), according to the guidelines of Korea Food and Drug Administration (KFDA). The erdosteine release from the two erodisteine capsules in vitro was tested using KP Ⅷ Apparatus Ⅱ method with various different kinds of dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty four healthy male subject, 23.33±2.06 years in age and 66.18±8.19 ㎏ in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After three capsules containing 300 ㎎ as erdostein were orally administered, blood was taken at predetermined time intervals and the concentrations of erdostein in serum were determined using HPLC method with UV detector. The dissolution profiles of two formulations were similar at all dissolution media. Besides, the pharmacokinetic parameters such as AUC_(t), C_(max) and T_(max) were calculated and ANOVA test was utilized for the statistical analysis of the parameters using log-arithmically transformed AUC_(t) and C_(max) and untransformed T_(max). The results showed that the differences between two formulations based on the Erdos were 0.20%, 1.10% and -9.44% for AUC_(t), C_(max) and T_(max), respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of long(0.8) to log(1.25)(e.g., long(0.94)∼long(1.22) and log(0.92)∼log(1.20) for AUC_(t) and C_(max), respectively. Thus, the criteria of the KFDA guidelines for the bioequivalence was satisfied, indicating Erblon capsule and Erdos capsule are bioequivalent.